PHARPharming Group N.V.
Price
-25%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, undemanding price, growth steady, the market undecided.
Pharming Group is a global biotechnology company that develops and commercializes innovative therapies for rare and ultra-rare diseases with significant unmet need. We focus on immunological and genetic conditions where our scientific and commercial expertise can help advance care over the long term. Patients are at the heart of everything we do. Their insights along with those of caregivers and the scientific community shape our strategy, guide our clinical study designs, and influence how we manage our approved therapies.
In the company’s own words · 20-F filed Apr 2, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
For the full year FY2025, revenue was $376M (+27% year on year) and net income $2.5M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.